ArticleAntimicrobial agents and chemotherapy2018
Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 116 citations in OpenAlex.
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- Peptoid-based antimicrobial strategies against polymyxin-resistant Gram-negative bacteria.Journal of applied microbiology · 2026Article
- Synthesis and synergistic antibacterial activity of rafoxanide derivative as a novel drug for potentiating colistin activity.Microbiology spectrum · 2026Article
- Colistin Resistance: From Laboratory Research to Modern Clinical Management.Antibiotics (Basel, Switzerland) · 2026Review
- Artificial Intelligence and the Discovery of Antibiotics: Reinventing with Opportunities, Challenges, and Clinical Translation.Antibiotics (Basel, Switzerland) · 2026Review
- In Vitro Evaluation of Colistin-Meropenem Activity Against XDR and PDR Carbapenemase-ProducingPathogens (Basel, Switzerland) · 2026Article
- Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus.The Journal of antimicrobial chemotherapy · 2026Article
- Synergistic effects of colistin-based combinations against colistin and carbapenem-resistant Klebsiella pneumoniae isolated from nosocomial bloodstream infections.Scientific reports · 2025Article
- A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.Medical microbiology and immunology · 2025Article
- De Novo Design and Asymmetric Synthesis of aOrganic letters · 2025Article
- Prevalence ofAntibiotics (Basel, Switzerland) · 2025Article
- Exploration of the Fusidic Acid Structure Activity Space for Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Article
- Discovery of new AMR drugs targeting modulators of antimicrobial activity using in vivo silkworm screening systems.The Journal of antibiotics · 2025Review
- Article
- In Vitro Synergistic Activity of Rifampicin Combined with Minimal Effective Antibiotic Concentration (MEAC) of Polymyxin B Against Extensively Drug-Resistant, Carbapenem-, and Polymyxin B-Resistant Klebsiella pneumoniae Clinical Isolates.Current microbiology · 2024Article
- Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria.Annals of clinical microbiology and antimicrobials · 2024Article
- Flavomycin restores colistin susceptibility in multidrug-resistant Gram-negative bacteria.mSystems · 2024Article
- Discovery of antibiotics that selectively kill metabolically dormant bacteria.Cell chemical biology · 2024Article
- A Review on Colistin Resistance: An Antibiotic of Last Resort.Microorganisms · 2024Review
- Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Resistance to colistin, a polypeptide drug used as an agent of last resort for the treatment of infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria, including carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.